Thus, future studies should evaluate the beneficial effects of targeting MPO and ANGPTL6 simultaneously for the treatment of both obesity and T2D by inhibiting the activity of MPO and overexpression of ANGPTL6. The gene discussed is ANGPTL6; the disease is obesity due to melanocortin 4 receptor deficiency.